Proteasome Inhibition for Antibody-Mediated Allograft Rejection

Seminars in Hematology

Volumn 49, Issue 3, 2012, Pages 263-269

  Sadaka, Basma ^a   Alloway, Rita R ^a   Shields, Adele R ^a   Schmidt, Nicole M ^a   Woodle, E Steve ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEASOME INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; SALINOSPORAMIDE A;

ANEMIA; ANTIBODY MEDIATED GRAFT REJECTION; ANTIBODY PRODUCTION; ARTICLE; BLOOD TOXICITY; BONE MARROW; BONE MARROW SUPPRESSION; CARDIAC GRAFT REJECTION; CLINICAL TRIAL (TOPIC); DEPLETION; DESENSITIZATION; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME STRUCTURE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; PANCREAS TRANSPLANTATION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CELL; PLASMAPHERESIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SERODIAGNOSIS; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; GRAFT REJECTION; HUMANS; PLASMA CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84862684056     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.04.008     Document Type: Article

References (37)

1. Lucas J.G., Co J.P., Nwaogwugwu U.T., Dosani I., Sureshkumar K.K. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother 2011, 12:579-592.
2. Walsh R.C., Everly J.J., Brailey P., et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010, 89:277-284.
3. Everly M.J., Everly J.J., Arend L.J., et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009, 9:1063-1071.
4. Mao Q., Terasaki P.I., Cai J., et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007, 7:864-871.
5. Lee P.C., Zhu L., Terasaki P.I., Everly M.J. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009, 88:568-574.
6. Mauiyyedi S., Colvin R.B. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002, 11:609-618.
7. Archdeacon P., Chan M., Neuland C., et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011, 11:896-906.
8. Ramos E.J., Pollinger H.S., Stegall M.D., Gloor J.M., Dogan A., Grande J.P. The effect of desensitization protocols on human splenic B-cell populations in-vivo. Am J Transplant 2007, 7:402-407.
9. Perry D.K., Burns J.M., Pollinger H.S., et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009, 9:201-209.
10. Everly M.J., Everly J.J., Susskind B., et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008, 86:1754-1761.
11. Racusen L.C., Colvin R.B., Solez K., Mihatsch M.J., Halloran P.F., Campbell P.M., et al. Antibody-mediated rejection criteria-an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003, 3:708-714.
12. Akalin E., Watschinger B. Antibody-mediated rejection. Semin Nephrol 2007, 27:393-407.
13. Liapis H., Wang H.L., Ritter J.H. Pathophysiology of solid organ transplantation 2011, 384. Springer, New York.
14. Gloor J.M., Cosio F.G., Rea D.J., et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006, 6:1841-1847.
15. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003, 29:3-9.
16. Kisselev A.F., Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001, 8:739-758.
17. Everly J.J., Walsh R.C., Alloway R.R., Woodle E.S. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009, 14:662-666.
18. Groll M., Koguchi Y., Huber R., Kohno J. Crystal structure of the 20S proteasome: TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol 2001, 311:543-548.
19. Sadaka B., Alloway R.R., Woodle E.S. Clinical and investigational use of proteasome inhibitors for transplant rejection. Expert Opin Investig Drugs 2011, 20:1535-1542.
20. Wu Y. On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am J Transplant 2002, 2:904-912.
21. Kloetzel P.M., Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004, 16:76-81.
22. Kim R., Emi M., Tanabe K., Murakami S. Role of the unfolded protein response in cell death. Apoptosis 2006, 11:5-13.
23. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
24. Walsh R.C., Brailey P., Girnita A., et al. Early and late acute antibody-mediated rejection differs immunologically and in response to proteasome inhibition. Transplantation 2011, 91:1218-1226.
25. Flechner S.M., Fatica R., Askar M., et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010, 90:1486-1492.
26. Woodle E.S., Light J., Franklin C., et al. A multicenter, prospective, collaborative evaluation of proteasome inhibition for the treatment of antibody mediated rejection in solid organ transplantation. Am J Transplant 2011, 10(suppl 4):159. (abstract 428).
27. Govil A., Walsh R.C., Tevar A., et al. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients. Clin Transpl 2010, 443-453.
28. Eckman P.M., Thorsgard M., Maurer D., Kim Y., Alloway R.R., Woodle E.S. Bortezomib for refractory antibody-mediated cardiac allograft rejection. Clin Transpl 2010, 475-478.
29. Morrow W.R., Frazier E.A., Mahle W.T., et al. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 2012, 93:319-324.
30. Neumann J., Tarrasconi H., Bortolotto An., Machuca T., Canabarro R. Acute humoral rejection in a lung recipient: reversion with bortezomib. Transplantation 2010, 89:125-126.
31. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
32. Orlowski R.Z., Nagler A., Sonneveld P., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007, 25:3892-3901.
33. Schmidt N, Alloway RR, Walsh RC, et al. Prospective evaluation of the toxicity profile of proteasome inhibitorbased therapy in renal transplant candidates and recipients. Transplantation. In press.
34. Moreau P., Coiteux V., Hulin C., et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 2008, 93:1908-1911.
35. Moreau P., Pylypenko H., Sebastian G., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority study. Lancet Oncol 2011, 12:431-440.
36. Potts B.C., Albitar M.X., Anderson K.C., et al. Marizomib, a proteasome inhibitor for all seasons: Preclinical profile and a framework. Curr Cancer Drug Targets 2011, 11:254-284.
37. Kuhn D.J., Orlowski R.Z., Bjorklund C.C. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets 2011, 11:285-295.